Leap <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces $58.9 Million Private Placement Led by Winklevoss Capital to Launch <a href="https://laohu8.com/S/DAAQU">Digital Asset</a> Treasury <a href="https://laohu8.com/S/MSTR">Strategy</a>
Leap Therapeutics Inc. (Nasdaq: LPTX), a biotechnology company specializing in targeted and immuno-oncology therapies, has announced a $58.88 million private placement led by Winklevoss Capital. The financing involves the sale of approximately 95.8 million shares of common stock or pre-funded warrants, along with additional warrants to purchase about 71.9 million shares at an exercise price of $0.5335 per share. The aggregate exercise price per unit is set at $0.61439. The funds raised will support Leap's newly initiated digital asset treasury strategy. Parcrest is serving as the placement agent, with Morgan, Lewis & Bockius LLP advising Leap and Cooley LLP advising Winklevoss Capital. The closing of the private placement is expected soon, pending customary closing conditions. Leap plans to provide further updates on its treasury activities in the near term.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE90771) on October 06, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。